. Effects of exercise and ␤2-agonists on lung function in chronic obstructive pulmonary disease.
DYSPNEA OCCURS DURING EXERCISE in subjects with chronic obstructive pulmonary disease (COPD), presumably because they must breathe at increased lung volume due to excessive flow limitation in the operative volume range (22) . Accordingly, in subjects with reversible airway obstruction, bronchodilators decrease dyspnea during exercise, and this is associated with a decrease in functional residual capacity (FRC) . In a number of COPD subjects, FRC decreases after a bronchodilator even in the absence of significant changes in forced expiratory volume in 1 s (FEV 1 ) or forced vital capacity (FVC) (21, 25) . The lack of sensitivity of FEV 1 and FVC to the effect of bronchodilators has been attributed to a bronchoconstrictor effect of the deep inhalation preceding the forced expiratory maneuver, which is often observed in chronic airway obstruction (8, 13, 25, 26, 31, 37) . It has therefore been postulated that the beneficial effect of bronchodilator treatments on symptoms and exercise tolerance may be overlooked by standard reversibility tests (21) , and the reduction of lung hyperinflation at rest may be a better predictor of benefits on exercise tolerance (22) . This may hold true if the bronchodilator effect is maintained during exercise. However, in subjects in whom a deep breath decreases flow, it may be expected that the increase of tidal volume (VT) during exercise also causes bronchoconstriction. This may offset the effect of pharmacological bronchodilatation, thus hindering its beneficial effects on airway hyperinflation and exercise tolerance.
This study was undertaken to investigate whether changes in airway caliber occur during exercise in COPD subjects and whether they modulate the effects of acute or chronic bronchodilator treatment.
METHODS

Subjects
Fifteen male subjects affected by moderate to severe COPD (1) took part in the study (Table 1 ). All were familiar with pulmonary function tests, because they had already participated in previous studies, were in stable clinical condition, and had not suffered from respiratory exacerbations in the previous 4 wk. No subject had a recent history of myocardial infarction or refractory heart failure or unstable arrhythmias that required treatment. The study protocol was approved by the local Ethics Committee, and informed consent was obtained from each participating subject.
Study Design
The following tests were made on a prestudy screening day: standard spirometry, absolute lung volumes, singlebreath lung carbon monoxide diffusion capacity, arterial blood gases, airway response to albuterol (200 g by metered dose inhaler and spacer), 12-lead electrocardiogram, dyspnea score (modified Medical Research Council scale), and maximal incremental exercise test.
The study consisted of a crossover phase and a subsequent parallel-group phase. In the crossover phase, subjects attended the laboratory on two separate occasions at the same time of day to have their resting lung function and response to exercise measured after treatment with placebo (day 1) or 200 g of albuterol (day 2) in a double-blind random sequence. Subjects were then randomized to a 3-wk doubleblind treatment with salmeterol (50 g bid, by metered dose inhaler) or placebo and attended the laboratory on a third occasion (day 3), within 3 h from the morning dose of treatment, to have resting lung function and response to exercise measured again.
Resting Lung Function Measurements
A Vmax 22 system and an Autobox V6200 (SensorMedics, Yorba Linda, CA) were used to measure lung function. Mouth flow was measured by a mass flow sensor, and volume was obtained by numerical integration of the flow signal. Partial and maximal flow-volume curves were obtained as follows. After at least four regular breaths, subjects forcefully expired from end-tidal inspiration to residual volume (RV), which was immediately followed by a fast inspiration to total lung capacity (TLC) and a second forced expiration to RV. The maneuvers were performed at least in triplicate until the reproducibility criteria for FEV 1 and FVC were met (2) . Flows at 30% of control FVC were measured on both maximal (V max30) and partial flow-volume curves (V part30), and their ratio (M/P) was calculated to quantify the effects of deep inhalation on airway caliber.
Thoracic gas volume was measured with subjects seated in the body plethysmograph and panting against a closed shutter at a frequency slightly Ͻ1 Hz with their cheeks supported. TLC was obtained as the sum of thoracic gas volume and the inspiratory capacity (IC) measured soon after reopening the shutter; RV was calculated as the difference between TLC and a slow expiratory vital capacity. FRC was obtained from thoracic gas volume corrected for any difference between the volume at which the shutter was closed and the average end-expiratory volume of the four preceding regular tidal breaths.
Single-breath carbon monoxide diffusion capacity was measured by using the method described by Huang and MacIntyre (17) . Blood samples were drawn from the radial artery, and gas tensions were measured by a Ciba Corning 855 gas analyzer (Ciba Corning Diagnostic, Medfield, MA).
Predicted values were from Quanjer et al. (32) for spirometry and lung volumes, and from Cotes et al. (11) for carbon monoxide diffusion capacity.
Exercise Test
A symptom-limited incremental exercise test was performed on an electronically braked cycle ergometer (Ergometrics 800, Ergoline, Bitz, Germany) with subjects wearing nose clips and breathing through a mass flow sensor (dead space ϭ 75 ml) connected to a saliva trap. Heart rate was continuously recorded (Archimed 4210, Esaote, Genoa, Italy). Oxygen uptake (V O2) and carbon dioxide output were measured breath by breath with rapid gas analyzers (Vmax, SensorMedics). Flow was continuously measured during inspiration and expiration and numerically integrated to obtain volumes. After a 5-min resting measurements period and a 3-min warm-up, exercise load was increased by 10 W every minute until the load could no longer be sustained; subjects pedaled at 50-60 revolutions/min. Special care was taken to maintain the position of the trunk fairly constant during the test. Predicted values were from Jones et al. (19) .
Sets of at least four to six regular tidal breaths immediately followed by a partial forced expiratory maneuver and an inspiration to TLC were obtained in triplicate at rest and individually over the last 30 s of each load step. Flow-volume curves were superimposed at TLC, which was assumed to remain constant throughout the test. This allowed changes in FRC, end-inspiratory lung volume, and V part 30 to be assessed during exercise. Changes of airway caliber on exercise were estimated by calculating the slope of the linear regression of all V part 30 values against minute ventilation (V E). VT, inspiratory and expiratory times, heart rate, carbon dioxide output, and V O2 were recorded over the last 30 s of each load step before recording the partial forced expiratory maneuver. The first three variables allowed breathing frequency (f), V E, and the ratio of inspiratory time to total respiratory cycle duration to be computed. The severity of breathlessness was assessed by using a modified Borg scale and a visual analog scale.
Statistical Analysis
The relationship between variables was tested by linear regression analysis and by Pearson's coefficient of correlation. Differences within groups were tested by paired Student's t-test. A two-factor repeated-measure analysis of variance with Duncan's post hoc test was used to compare the effect of treatments between groups. P values of Ͻ0.05 were considered statistically significant. Values are presented as means Ϯ SD.
RESULTS
Crossover Phase
Resting lung function. After albuterol treatment (day 2), mean FEV 1 was slightly but significantly larger than after placebo treatment (day 1) ( Table 2 ). This was associated with significant increments of V max 30 , V part 30 , IC, and inspiratory vital capacity, and with significant decrements of FRC and RV, which is suggestive of effective bronchodilation. The M/P ratio at rest was significantly Ͻ1 (P Ͻ 0.01) on both days 1 and 2, indicating a bronchoconstrictor effect of deep inhalation. Respiratory symptoms also improved after albuterol, as documented by a decrease of both Borg (P Ͻ 0.05) and visual analog scale (P Ͻ 0.05) scores.
Response to exercise. After placebo treatment (day 1), both maximum workload and V O 2 were well below the predicted normal values (Table 3) . Peak V E was 72 Ϯ 16% of maximum voluntary ventilation, as assessed by FEV 1 ⅐ 35, and heart rate was below the lower predicted values. In general, maximum exercise was variably limited by ventilation, physical deconditioning, and cardiovascular response. Exercise hyperpnea was achieved by increasing both VT and f. The slope of V part 30 vs. V E could be reliably determined in 13 subjects and was insignificantly different from zero (Ϫ0.008 Ϯ 0.015) but negative in 10 cases, which suggests that further airway narrowing occurred during exercise in most subjects.
After albuterol treatment (day 2), the main variables of exercise test (maximum workload and V O 2 ), breathing pattern (V E, VT, f, FRC, end-inspiratory lung volume), and respiratory symptom scores recorded at maximum exercise were not significantly different from day 1. The slope of V part 30 vs. V E could be reliably determined in 12 subjects and was significantly different from zero (Ϫ0.016 Ϯ 0.016; P Ͻ 0.05).
The slope of V part 30 vs. V E was significantly correlated with the M/P ratio at rest (Fig. 1 ) both on day 1 (r ϭ 0.71, P Ͻ 0.01) and day 2 (r ϭ 0.63, P Ͻ 0.05), suggesting that the greater the bronchoconstrictor effect of deep inhalation at rest the greater the airway narrowing during exercise. Furthermore, the slope of V part 30 vs. VT, but not vs. f, was significantly correlated with the M/P ratio at rest both on day 1 (r ϭ 0.65, P Ͻ 0.05) and day 2 (r ϭ 0.61, P Ͻ 0.05). In most individuals, FRC increased with V E after either placebo or albuterol treatment, and this increase was significantly correlated with the V part 30 vs. V E slope (Fig. 2) both on day 1 (r ϭ Ϫ0.62, P Ͻ 0.05) and day 2 (r ϭ Ϫ0.69, P Ͻ 0.05). Partial and tidal flow-volume loops of a representative subject at rest and during exercise are shown in Fig. 3 .
Parallel-Group Phase
Resting lung function. Treatment for 3 wk with salmeterol in nine patients was associated with a significant increase in V part 30 (P Ͻ 0.05) ( Table 4) . Both Borg and visual analog scale tended to decrease, although this did not achieve statistical significance. None of the lung function variables was significantly changed after placebo treatment compared with day 1. Values are means Ϯ SD; n ϭ 15 subjects. V max30 and V part30, maximal and partial forced expiratory flows at 30% of control FVC, respectively; IC, inspiratory capacity; IVC, inspiratory vital capacity. Significant difference vs. day 1: *P Ͻ 0.05; † P Ͻ 0.01; ‡ P Ͻ 0.001. Values are means Ϯ SD; n ϭ 15 subjects. HR, heart rate; V O2, oxygen uptake; V E, minute ventilation; VT, tidal volume; EILV, end-inspiratory lung volume; f, breathing frequency; TI / Ttot, ratio of inspiratory time to total respiratory cycle duration; VAS, visual analog scale. Significantly different from day 1: * P Ͻ 0.05; † P ϭ 0.052. 30 and/or IC beyond the limits of spontaneous variability (25) in four of nine subjects treated with salmeterol, no difference was observed in any parameter of physical performance, breathing pattern, or respiratory symptoms compared with day 1 ( Table 5 ). The average slope of V part 30 vs. V E was still negative with salmeterol treatment (Ϫ0.011 Ϯ 0.030), although it was not significantly different from zero and from placebo treatment (Ϫ0.016 Ϯ 0.019), suggesting that the long-term bronchodilator effect of salmeterol was also offset by bronchoconstriction that occurred during exercise.
Response to exercise. Despite an increase in V part
DISCUSSION
The main findings of this study are that 1) airway narrowing occurs during exercise in a number of COPD subjects, and the magnitude of this effect is related to the bronchoconstrictor effect of deep inhalation at rest; 2) the reduction of expiratory flows during exercise contributes to lung hyperinflation with hyperpnea; and 3) the bronchoconstrictor effect of exercise may offset pharmacologically induced bronchocodilatation.
Comments on Methodology
In the present study, changes in airway caliber during exercise were assessed by measuring partial forced expiratory flows at various steps of exercise, according to a technique previously used (5, 27) and based on two assumptions. First, partial flows reflect changes in airway caliber relevant to each step of exercise better than maximal flows because they are not affected by the effect of lung inflation (8-10, 26, 27) . Second, with the assumption that TLC remains constant with exercise (38), a full inflation taken soon after the maneuver allows the tidal flow-volume loops to be superimposed on the volume axis; thus assessment of flow at constant lung volume, namely 30% of control FVC in this study, was allowed. Values are means Ϯ SD; n ϭ 9 for salmeterol group and 6 for placebo group. * P Ͻ 0.05 vs. day 1. Values are means Ϯ SD; n ϭ 9 for salmeterol group and 6 for placebo group.
Maximal and partial flow volume curves were obtained by plotting flow against expired volume, thus the effects of thoracic gas compression were not taken into account. In theory, more thoracic gas compression on maximal than on partial expiratory maneuver could result in M/P ratios of Ͻ1, and this effect should be greater in the more hyperinflated subjects. However, there are reasons to be confident that this phenomenon was unimportant in this study. In asthma, thoracic gas compression was found to be similar (24) on maximal and partial flow-volume curves or slightly greater on the former (14) , but by an amount that is unlikely to be appreciable when the downslope of the flow-volume curves is flat, as in the severely obstructed subjects of this study. Moreover, in asthma, changes in flow and airway resistance after a deep breath occur in the same direction and proportion (28, 30) . Finally, in this study, no correlation was found between baseline M/P ratio and indexes of lung hyperinflation, namely FRC and TLC as a percent of predicted values.
Comments on Results
Bronchodilatation generally occurs during physical exercise not only in healthy subjects but also in those with bronchial asthma or mild COPD (3, 16, 18, 27, 34) , thus widening the flow-volume loop and ultimately increasing the expiratory flow reserve. As a result, the breathing constraints mostly represented by the occurrence of expiratory airflow limitation and dynamic hyperinflation disappear or occur at higher levels of ventilation. Although unknown, mechanisms such as continuous stretching imposed by the lung on the airway wall, release of bronchodilator mediators (adrenaline, nitric oxide, etc.), and decrement in vagal tone may contribute to increase airway caliber possibly acting at the smooth muscle level (3, 12, 16, 18, 27, 34) . In the present study, exercise hyperpnea was associated with airway narrowing, especially after inhalation of a regular dose of albuterol, which suggests that the above bronchodilator mechanisms were not operative in these subjects or were counteracted by some bronchoconstrictor mechanisms.
Bronchoconstriction may also occur during exercise in subjects with exercise-induced asthma (6, 35, 36) , which has been attributed to a series of mechanisms, such as local release of mediators, osmotic changes at the airways level (4), and myogenic reflexes of the airway smooth muscles (29) . Whether these bronchoconstrictor mechanisms are also operative in COPD is unknown, but the absence of sustained bronchoconstriction after the repeated deep inhalations used to assess baseline lung function in these subjects makes it unlikely that constriction during exercise was mediated by a release of mediators or myogenic reflexes.
In subjects with chronic airflow obstruction, further airway narrowing is often observed after a deep inhalation is taken (8, 13, 25, 31) . Potential physiological explanations for this phenomenon are a reduced volume excursion due to lung hyperinflation, low elastic recoil, stress relaxation, altered airway-to-parenchymal interdependence, relative predominance of parenchymal hysteresis over airway hysteresis, and inhomogeneity of lung emptying during forced expiration (15, 20, 26) . Whatever the underlying mechanisms, whose discussion is beyond the scope of this paper, it is a fact that airflow obstruction occurs after taking a full lung inflation in many COPD patients (8, 13, 25, 26) . The positive correlation between the slope of V part 30 vs. V E and the M/P ratio at rest observed in this study suggests that, in those subjects in whom deep inhalation causes bronchoconstriction, the increase in V E with exercise may also cause airway narrowing. The large variability in both V part 30 vs. V E and M/P ratio may be accounted for by the heterogeneous nature of COPD (23) .
The failure of bronchodilator treatments to reduce airflow limitation and symptoms during exercise can be explained by two mechanisms. First, a greater bronchoconstrictor effect of deep inhalation was observed in most individuals after albuterol, as indicated by further reduction in V part 30 vs. V E slope, which became significantly Ͻ0. This was possibly due to a decrease in airway hysteresis as a consequence of a pharmacologically induced reduction in airway smooth muscle tone (33, 37) or to a decrease in airway wall stiffness. These findings may appear at variance with those of Belman et al. (7) and O'Donnell et al. (22) , who reported an increase in exercise performance and a reduction in dyspnea during exercise after treatment with bronchodilators. A possible explanation for this difference is that the researchers mostly studied subjects in whom the negative effect of volume history on airway caliber was absent or minimal, as was the case with some of the subjects of the present study. Moreover, with partial flows that remained low during exercise, FRC had to increase similarly with and without bronchodilators (Fig. 2) , which was likely to meet the ventilatory demands or act as a reaction to airway dynamic compression (5, 18, 27) . In agreement with Belman et al. and O'Donnell et al., the lack of benefit from bronchodilators on respiratory symptoms at maximum workload could be explained by the same degree of lung hyperinflation achieved during exercise with and without bronchodilators.
The findings of the present study raise the question of whether the severity of the disease is based on the response to deep inhalations. The data would indicate that the COPD patients in whom a deep breath at rest evokes airflow obstruction may still take advantage of bronchodilator drugs at rest, which was suggested by improvement of respiratory symptoms and lung function (decrease in FRC and increase in partial flows), but this cannot be seen with parameters preceded by full lung inflation (FEV 1 and/or FVC). However, because of the negative effect of volume history, subjects may show airflow obstruction during exercise, which would thus make pharmacologically induced bronchodilatation ineffective. In contrast, COPD patients without bronchoconstriction induced by deep inhalation may take advantage of bronchodilator treatments equally at rest and during exercise.
In conclusion, the present study indicates that airflow obstruction may occur during exercise in COPD subjects and is related to the bronchoconstrictor effect of the deep inhalation at rest. This effect may be sufficient in a number of subjects to offset the beneficial effect of bronchodilator drugs revealed at rest by using lung function measurements not affected by volume history.
